<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02823808</url>
  </required_header>
  <id_info>
    <org_study_id>KNDP_IIT_2016_01</org_study_id>
    <nct_id>NCT02823808</nct_id>
  </id_info>
  <brief_title>Effect of Alogliptin/Pioglitazone on the Preservation of Long-term Beta-cell Function</brief_title>
  <official_title>Effect of Alogliptin/Pioglitazone on the Preservation of Long-term Beta-cell Function After Early Intensive Diabetes Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyunghee University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kyung Hee University Hospital at Gangdong</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bucheon St. Mary's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Korea University Guro Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ajou University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Inha University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kangbuk Samsung Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Seoul Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Kyunghee University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      All subjects will be randomized as Alo/Pio combo group (intervention) or Glim/Met combo group
      (control) after intensive COAD treatment based on identical protocol.

        -  All subject will be managed with once daily, fixed dose, single tablet treatment based
           on the study protocol, and followed-up for 104 weeks.

        -  Any group of subjects who fail to reach glycemic target with single tablet treatment,
           subject will be treated with rescue medication and stopped regular observation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">July 2017</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative treatment failure (HbA1câ‰¥7.0%) rate for glycemic control</measure>
    <time_frame>104 weeks from randomization</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c</measure>
    <time_frame>104 weeks from randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Blood Sugar</measure>
    <time_frame>104 weeks from randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Glycoalbumin</measure>
    <time_frame>104 weeks from randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in insulin sensitivity (HOMA2%S)</measure>
    <time_frame>104 weeks from randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in insulin sensitivity (HOMA2%B)</measure>
    <time_frame>104 weeks from randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in proinsulin</measure>
    <time_frame>104 weeks from randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in glucagon</measure>
    <time_frame>104 weeks from randomization</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>ALO+PIO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group who takes Alogliptin 25mg+Pioglitazone 15mg, once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GMPD+MET</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group who takes Glimepiride 2mg+Metformin 500mg, once daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NESINA ACT TAB. 25/15mg</intervention_name>
    <description>Alogliptin/Pioglitazone 25/15mg will be administered to the group once a day in a fixed dose on a fixed schedule for 104 week.</description>
    <arm_group_label>ALO+PIO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMARYL-M TAB. 2/500mg</intervention_name>
    <description>Glymepiride/Metformin 2/500mg will be administered to the group once a day in a fixed dose on a fixed schedule for 104 week.</description>
    <arm_group_label>GMPD+MET</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 Diabetes Mellitus patients

          -  Patient who had been diagnosed within the previous 12 months with HbA1c levels of
             8.0-12.0%, did not have a medical history related to diabetes, and did not display
             proliferative retinopathy

        Exclusion Criteria:

          -  The use of weight-lowering drugs, any investigational blood-glucose or lipid-lowering
             agent (other than statins or ezetimibe) within the past 3 months

          -  Previous treatment with systemic corticosteroids or a change in dosage of thyroid
             hormones in the previous 6 weeks

          -  The use of insulin within the 3 months prior to screening

          -  Others
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>26 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeong-taek Woo</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kyung Hee University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jeong-taek Woo</last_name>
    <phone>822-958-8200</phone>
    <email>jtwoomd@khmc.or.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sang Youl Rhee</last_name>
    <phone>822-958-8200</phone>
    <email>bard95@hanmail.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kyunghee University Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sang Youl Rhee</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 1, 2016</study_first_submitted>
  <study_first_submitted_qc>July 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 6, 2016</study_first_posted>
  <last_update_submitted>July 21, 2017</last_update_submitted>
  <last_update_submitted_qc>July 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kyunghee University Medical Center</investigator_affiliation>
    <investigator_full_name>Jeong-taek Woo</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
    <mesh_term>Alogliptin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

